Changeflow GovPing Pharma & Drug Safety PTGS2 Skin Disorders Carnosine Compound Treatme...
Routine Notice Added Final

PTGS2 Skin Disorders Carnosine Compound Treatment Method

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO published patent application US20260096978A1 disclosing a method for preventing, mitigating, or treating PTGS2-induced skin disorders using carnosine compounds of formula (I) applied to human skin. The application, filed November 14, 2022, names five inventors and covers cosmetic and dermatological formulations.

What changed

USPTO published patent application US20260096978A1 for a method using carnosine compounds (formula I, where R1=H/CH3 and R2=H/COOH) to prevent, mitigate, or treat PTGS2-induced skin disorders and related dysfunctions. The application covers non-therapeutic topical applications to human skin.

Pharmaceutical and cosmetic companies developing skin disorder treatments should monitor this application for potential licensing or design-around considerations. The broad claims covering PTGS2-induced disorders and carnosine derivatives may impact freedom-to-operate analyses for dermatological product developers.

What to do next

  1. Monitor for patent prosecution updates
  2. Review freedom-to-operate for skin disorder treatments
  3. Evaluate potential licensing opportunities

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS

Application US20260096978A1 Kind: A1 Apr 09, 2026

Inventors

Dominik STUHLMANN, Maria REICHENBACH, Paul SLAVASHEVICH, Christina GIRARDI, Michele MASSIRONI

Abstract

Suggested is a non-therapeutic method for preventing, mitigating or treating PTGS2-induced disorders of human skin and related dysfunctions, comprising or consisting of the following step: —applying a working amount of a carnosine compound according to formula (I) in which R1 stands for H or CH3 and R2 for H or COOH, to human skin

CPC Classifications

A61K 8/64 A61K 38/05 A61P 17/16 A61Q 17/04 A61Q 19/08

Filing Date

2022-11-14

Application No.

19110636

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260096978A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Pharmaceutical research Cosmetic formulation
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.